Literature DB >> 19293310

A prospective study of relative telomere length and postmenopausal breast cancer risk.

Immaculata De Vivo1, Jennifer Prescott, Jason Y Y Wong, Peter Kraft, Susan E Hankinson, David J Hunter.   

Abstract

During breast cancer progression, a substantial increase in chromosomal aberrations is observed in the transition from ductal hyperplasia to carcinoma in situ. Telomeres are essential structures to chromosomal integrity. Consequently, telomere dysfunction, which leads to genomic instability, is hypothesized to play a causal role in the progression of breast cancer. However, the few epidemiologic studies that have assessed the relationship between telomere length and breast cancer risk have been inconsistent. We used quantitative real-time PCR to measure relative telomere length in genomic DNA extracted from peripheral blood leukocytes and examined its association with postmenopausal breast cancer risk in 1,122 invasive breast cancer cases and 1,147 matched controls free of diagnosed cancer nested within the prospective Nurses' Health Study. Our data show that relative telomere length was not associated with a significant elevation in postmenopausal breast cancer risk [below versus above median; odds ratio, 1.23; 95% confidence interval, 0.94-1.60; P(trend) = 0.20]. Estrone and estradiol hormone levels were significantly inversely associated with relative telomere length (P = 0.02). Other established breast cancer risk factors such as family history of breast cancer and history of benign breast disease were not associated with relative telomere length in separate linear regression models each adjusted for age and disease status (P > or = 0.07). Our results provide little support for an important role of telomere length, as measured in peripheral blood leukocytes, as a biomarker of breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293310      PMCID: PMC2732000          DOI: 10.1158/1055-9965.EPI-08-0998

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  19 in total

1.  Telomere measurement by quantitative PCR.

Authors:  Richard M Cawthon
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

Review 2.  Telomerase activity in human cancer.

Authors:  J W Shay; W E Wright
Journal:  Curr Opin Oncol       Date:  1996-01       Impact factor: 3.645

3.  Telomere length in different tissues of elderly patients.

Authors:  U Friedrich; E Griese; M Schwab; P Fritz; K Thon; U Klotz
Journal:  Mech Ageing Dev       Date:  2000-11-15       Impact factor: 5.432

4.  Breast cancer survival is associated with telomere length in peripheral blood cells.

Authors:  Ulrika Svenson; Katarina Nordfjäll; Birgitta Stegmayr; Jonas Manjer; Peter Nilsson; Björn Tavelin; Roger Henriksson; Per Lenner; Göran Roos
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

5.  Telomere length predicts replicative capacity of human fibroblasts.

Authors:  R C Allsopp; H Vaziri; C Patterson; S Goldstein; E V Younglai; A B Futcher; C W Greider; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

6.  Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue.

Authors:  A A van Landeghem; J Poortman; M Nabuurs; J H Thijssen
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

7.  Telomere dysfunction: a potential cancer predisposition factor.

Authors:  Xifeng Wu; Christopher I Amos; Yong Zhu; Hua Zhao; Barton H Grossman; Jerry W Shay; Sherry Luo; Waun Ki Hong; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

8.  Reproducibility and validity of self-reported menopausal status in a prospective cohort study.

Authors:  G A Colditz; M J Stampfer; W C Willett; W B Stason; B Rosner; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

9.  In situ analyses of genome instability in breast cancer.

Authors:  Koei Chin; Carlos Ortiz de Solorzano; David Knowles; Arthur Jones; William Chou; Enrique Garcia Rodriguez; Wen-Lin Kuo; Britt-Marie Ljung; Karen Chew; Kenneth Myambo; Monica Miranda; Sheryl Krig; James Garbe; Martha Stampfer; Paul Yaswen; Joe W Gray; Stephen J Lockett
Journal:  Nat Genet       Date:  2004-08-08       Impact factor: 38.330

10.  Is telomere length in peripheral blood lymphocytes correlated with cancer susceptibility or radiosensitivity?

Authors:  J Barwell; L Pangon; A Georgiou; Z Docherty; I Kesterton; J Ball; R Camplejohn; J Berg; A Aviv; J Gardner; B S Kato; N Carter; D Paximadas; T D Spector; S Hodgson
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640

View more
  80 in total

1.  Physical activity, sedentary behavior, and leukocyte telomere length in women.

Authors:  Mengmeng Du; Jennifer Prescott; Peter Kraft; Jiali Han; Edward Giovannucci; Susan E Hankinson; Immaculata De Vivo
Journal:  Am J Epidemiol       Date:  2012-02-01       Impact factor: 4.897

2.  U-shaped association between telomere length and esophageal squamous cell carcinoma risk: a case-control study in Chinese population.

Authors:  Jiangbo Du; Wenjie Xue; Yong Ji; Xun Zhu; Yayun Gu; Meng Zhu; Cheng Wang; Yong Gao; Juncheng Dai; Hongxia Ma; Yue Jiang; Jiaping Chen; Zhibin Hu; Guangfu Jin; Hongbing Shen
Journal:  Front Med       Date:  2015-11-18       Impact factor: 4.592

3.  Race-related health disparities and biological aging: does rate of telomere shortening differ across blacks and whites?

Authors:  Marissa Rewak; Stephen Buka; Jennifer Prescott; Immaculata De Vivo; Eric B Loucks; Ichiro Kawachi; Amy L Non; Laura D Kubzansky
Journal:  Biol Psychol       Date:  2014-03-29       Impact factor: 3.251

4.  Telomere length and mortality following a diagnosis of ovarian cancer.

Authors:  Joanne Kotsopoulos; Jennifer Prescott; Immaculata De Vivo; Isabel Fan; John Mclaughlin; Barry Rosen; Harvey Risch; Ping Sun; Steven A Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-26       Impact factor: 4.254

5.  Telomere length and cancer mortality in American Indians: the Strong Heart Study.

Authors:  Pooja Subedi; Stefano Nembrini; Qiang An; Yun Zhu; Hao Peng; Fawn Yeh; Shelley A Cole; Dorothy A Rhoades; Elisa T Lee; Jinying Zhao
Journal:  Geroscience       Date:  2019-06-22       Impact factor: 7.713

Review 6.  Epidemiologic evidence for a role of telomere dysfunction in cancer etiology.

Authors:  Jennifer Prescott; Ingrid M Wentzensen; Sharon A Savage; Immaculata De Vivo
Journal:  Mutat Res       Date:  2011-07-02       Impact factor: 2.433

7.  Telomere length varies by DNA extraction method: implications for epidemiologic research.

Authors:  Julie M Cunningham; Ruth A Johnson; Kristin Litzelman; Halcyon G Skinner; Songwon Seo; Corinne D Engelman; Russell J Vanderboom; Grace W Kimmel; Ronald E Gangnon; Douglas L Riegert-Johnson; John A Baron; John D Potter; Robert Haile; Daniel D Buchanan; Mark A Jenkins; David N Rider; Stephen N Thibodeau; Gloria M Petersen; Lisa A Boardman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-09       Impact factor: 4.254

8.  Leukocyte telomere length and age at menopause.

Authors:  Kristen E Gray; Melissa A Schiff; Annette L Fitzpatrick; Masayuki Kimura; Abraham Aviv; Jacqueline R Starr
Journal:  Epidemiology       Date:  2014-01       Impact factor: 4.822

9.  Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.

Authors:  Debra Lyon; Lynne Elmore; Noran Aboalela; Jacqueline Merrill-Schools; Nancy McCain; Angela Starkweather; R K Elswick; Colleen Jackson-Cook
Journal:  Biol Res Nurs       Date:  2013-04-11       Impact factor: 2.522

Review 10.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.